|
|
Eli Lilly And Company (NYSE: LLY) |
|
|
|
| |
LLY's Revenue Growth by Quarter and Year
Eli Lilly And's Revenue results by quarter and year
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
| LLY Revenue (in millions $) |
FY 2024 |
FY 2023 |
FY 2022 |
FY 2021 |
| IV Quarter |
December |
-
|
9,353.40
|
7,301.80
|
7,999.90
|
| III Quarter |
September |
11,439.10
|
9,498.60
|
6,941.60
|
6,772.80
|
| II Quarter |
June |
11,302.80
|
8,312.10
|
6,488.00
|
6,740.10
|
| I Quarter |
March |
8,768.00
|
6,960.00
|
7,810.00
|
6,805.60
|
| FY |
|
31,509.90
|
34,124.10
|
28,541.40
|
28,318.40
|
| LLY Revenue third quarter 2024 Y/Y Growth Comment |
Eli Lilly And Company achieved in the third quarter 2024, above Company average Revenue growth of 20.43% year on year, to $ 11,439.10 millions.
Looking into third quarter 2024 results within Major Pharmaceutical Preparations industry 36 other companies have achieved higher Revenue growth. While Eli Lilly And Company' s Revenue rise of 20.43% ranks overall at the positon no. 289 in the third quarter 2024.
|
| LLY Revenue ( Y/Y Growth %) |
2024
|
2023 |
2022 |
2021 |
| IV Quarter |
December |
- |
28.1 % |
-8.73 % |
7.53 % |
| III Quarter |
September |
20.43 % |
36.84 % |
2.49 % |
17.98 % |
| II Quarter |
June |
35.98 % |
28.11 % |
-3.74 % |
22.56 % |
| I Quarter |
March |
25.98 % |
-10.88 % |
14.76 % |
16.14 % |
| FY |
|
- |
19.56 % |
0.79 % |
15.4 % |
LLY Revenue (Quarter on Quarter Growth %) |
2024
|
2023 |
2022 |
2021 |
| IV Quarter |
December |
- |
-1.53 % |
5.19 % |
18.12 % |
| III Quarter |
September |
1.21 % |
14.27 % |
6.99 % |
0.49 % |
| II Quarter |
June |
28.91 % |
19.43 % |
-16.93 % |
-0.96 % |
| I Quarter |
March |
-6.26 % |
-4.68 % |
-2.37 % |
-8.53 % |
| FY (Year on Year) |
|
- |
19.56 % |
0.79 % |
15.4 % |
| Revenue Y/Y Growth Statistics |
| High |
Average |
Low |
| 36.84 % |
6.19 % |
-16.76 % |
| (Sep 30 2023) |
|
(June 30. 2014) |
|
|
| Revenue Y/Y Growth Statistics |
| High |
Average |
Low |
| 36.84 % |
6.19 % |
-16.76 % |
| (Sep 30 2023) |
|
(June 30. 2014) |
|
| Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024 |
Eli Lilly And's Q/Q Revenue Growth
| Revenue Q/Q Growth Statistics |
| High |
Average |
Low |
| 29.6 % |
1.88 % |
-28.64 % |
|
|
|
| LLY's III. Quarter Q/Q Revenue Comment |
Eli Lilly And Company achieved in the III. Quarter 2024 below company average Revenue growth of 1.21% quarter on quarter, to $ 11,439.10 millions.
Within Major Pharmaceutical Preparations industry 18 other companies have achieved higher Revenue quarter on quarter growth. While Eli Lilly And's Revenue growth quarter on quarter, overall rank is 433. |
|
|
|
| Revenue Q/Q Growth Statistics |
| High |
Average |
Low |
| 29.6 % |
1.88 % |
-28.64 % |
|
|
|
| LLY's III. Quarter Q/Q Revenue Comment |
Eli Lilly And Company achieved in the III. Quarter 2024 below company average Revenue growth of 1.21% quarter on quarter, to $ 11,439.10 millions.
Within Major Pharmaceutical Preparations industry 18 other companies have achieved higher Revenue quarter on quarter growth. While Eli Lilly And's Revenue growth quarter on quarter, overall rank is 433. |
|
Eli Lilly And's 12 Months Revenue Growth Year on Year
Revenue TTM Growth |
12 Months Ending
(Sep 30 2024) |
12 Months Ending
(Jun 30 2024) |
12 Months Ending
(Mar 31 2024) |
12 Months Ending
(Dec 31 2023) |
12 Months Ending
(Sep 30 2023) |
| Cumulative Revenue 12 Months Ending |
$ 40,863.30 |
$ 38,922.80 |
$ 35,932.10 |
$ 34,124.10 |
$ 32,072.50 |
| Y / Y Revenue Growth (TTM) |
27.41 % |
31.87 % |
29.76 % |
19.56 % |
9.69 % |
| Year on Year Revenue Growth Overall
Ranking |
# 212 |
# 1119 |
# 2037 |
# 802 |
# 1747 |
| Seqeuential Revenue Change (TTM) |
4.99 % |
8.32 % |
5.3 % |
6.4 % |
8.66 % |
| Seq. Revenue Growth (TTM) Overall
Ranking |
# 230 |
# 1013 |
# 1892 |
# 920 |
# 2165 |
| Cumulative Revenue growth
Comment |
Assuming the Eli Lilly And's fiscal year would have ended in Sep 30 2024, Eli Lilly And would have reprted above average annual Revenue rise of 27.41% year on year, of $ 40,863 millions.
This marks a slow-down of the companys growth trends and from the 31.87% improvement in Jun 30 2024.
Within the Healthcare sector 34 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 212, from total ranking in previous quarter at 1119. |
| Revenue TTM Q/Q Growth Statistics |
| High |
Average |
Low |
31.87 % |
5.84 % |
-15.13 % |
|
|
|
|
|
| Revenue TTM Y/Y Growth Statistics |
| High |
Average |
Low |
31.87 % |
5.84 % |
-15.13 % |
|
|
|
| Revenue TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 10 |
| Sector |
# 36 |
| S&P 500 |
# 230 |
|
| Cumulative Revenue growth
Comment |
Assuming the Eli Lilly And's fiscal year would have ended in Sep 30 2024, Eli Lilly And would have reprted above average annual Revenue rise of 27.41% year on year, of $ 40,863 millions.
This marks a slow-down of the companys growth trends and from the 31.87% improvement in Jun 30 2024.
Within the Healthcare sector 34 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 212, from total ranking in previous quarter at 1119. |
| Revenue TTM Q/Q Growth Statistics |
| High |
Average |
Low |
31.87 % |
5.84 % |
-15.13 % |
|
|
|
| Revenue TTM Y/Y Growth Statistics |
| High |
Average |
Low |
31.87 % |
5.84 % |
-15.13 % |
|
|
|
| Revenue TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 10 |
| Sector |
# 36 |
| S&P 500 |
# 230 |
|
35.64%